J 2019

Wharton’s Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro

CORSELLO, Tiziana, Amico GIANDOMENICO, Simona CORRAO, Rita ANZALONE, Francesca TIMONERI et. al.

Základní údaje

Originální název

Wharton’s Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro

Autoři

CORSELLO, Tiziana (380 Itálie), Amico GIANDOMENICO (380 Itálie), Simona CORRAO (380 Itálie), Rita ANZALONE (380 Itálie, garant), Francesca TIMONERI (380 Itálie), Melania LO IACONO (380 Itálie), Eleonora RUSSO (380 Itálie), Giovanni Francesco SPATOLA (380 Itálie), Maria Laura UZZO (380 Itálie), Mario GIUFFRÈ (380 Itálie), Martin CAPRNDA (703 Slovensko), Peter KUBATKA (703 Slovensko), Peter KRUŽLIAK (703 Slovensko, domácí), Pier Giulio CONALDI (380 Itálie) a Giampiero LA ROCCA (380 Itálie)

Vydání

Stem Cell Reviews and Reports, SPRINGER, 2019, 2629-3269

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10601 Cell biology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.316

Kód RIV

RIV/00216224:14110/19:00113179

Organizační jednotka

Lékařská fakulta

UT WoS

000511707800013

Klíčová slova anglicky

Wharton’s jelly mesenchymal stromal cells; Immunomodulation; CD276; B7-H3; Lymphocyte inhibition; Stem cells; Human umbilical cord; Regenerative medicine; Cell therapy

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 12. 3. 2020 15:36, Mgr. Tereza Miškechová

Anotace

V originále

Therapeutic options for end-stage organ failure are often limited to whole organ transplantation. The tolerance or rejection of the transplanted organ is driven by both early non-specific innate and specific adaptive responses. The use of mesenchymal stromal cells (MSCs) is considered a promising tool in regenerative medicine. Human umbilical cord (HUC) is an easily available source of MSCs, without relevant ethical issues. Moreover, Wharton’s jelly-derived MSCs (WJ-MSCs), showed consistent immunomodulatory features that may be useful to promote immune tolerance in the host after transplantation. Few data are available on the phenotype of WJ-MSCs in situ. We investigated the expression of immune-related molecules, such as HLAs, IDO, CD276/B7-H3, and others, both in situ (HUC) and in in vitro-cultured WJ-MSCs. Morphological and biochemical techniques were used to define the expression of such molecules. In addition, we focused on the possible role of CD276/B7-H3 on T cells proliferation inhibition. We assessed CD276/B7-H3 expression by WJ-MSCs both in situ and alongside cell culture. WJ-MSCs were able to suppress T cell proliferation in mixed lymphocyte reaction (MLR). Moreover, we describe for the first time a specific role for CD276/B7-H3, since the immunomodulatory ability of WJ-MSCs was abolished upon anti-CD276/B7-H3 antibody addition to the MLR. These results further detail the immune regulation properties and tolerance induction exerted by human WJ-MSCs, in particular pointing to CD276/B7-H3 as one of the main involved factors. These data further suggest WJ-MSCs as potent tools to modulate local immune response in “support-type” regenerative medicine approaches.